Why CureVac Shares Are Trading Lower Today

CureVac BV CVAC shares are trading lower by 3.6% at $56 after the CDC said preliminary findings suggest the observed reports of heart inflammation after mRNA COVID-19 vaccines are greater than expected.

CureVac a clinical-stage biopharmaceutical company, developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people.

CureVac's product portfolio also includes clinical and pre-clinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy.

Among CureVac's clinical programs are CV8102, which it is evaluating in Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it's investigating in Phase 1 clinical trial for potential vaccination against rabies.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Short IdeasMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!